AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02391324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lokomat (LOK)
Description: Physical therapy provided using a robotic gait training system (Lokomat).
Study NCT02391324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gait focused physical therapy (fPT)
Description: Overground physical therapy focussed on enhancing gait related motor skills
Study NCT02391324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LOK + fPT
Description: A combination of robotic gait training and gait focussed functional physical therapy.
Study NCT03762161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS 102
Description: Participant self-administered orally at 35 milligrams per meter squared (mg/m2) twice daily Days 1-5 and 8-12 of every 28 day cycle
Study NCT02043184 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Voice Response (IVR) Reminders
Description: Reminders tailored to the oral cancer medication(s) the patients are receiving delivered by interactive voice response system with referral to a self-management guide when symptoms exceed thresholds.
Study NCT04623463 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical activity intervention
Description: Participants included in the present study will benefit from a 4-week physical activity intervention. Upon the initial visit, a physical activity prescription will be defined and they will be equipped with a physical activity monitor that allows feedback. Participants will then exercise one day per week on-site and 4 days/week on their own. Weekly physical activity will be reviewed weekly with the participant during their on-site visit.
Study NCT03716453 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard protocol
Description: Give narcotic according to vital signs
Study NCT03716453 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ANI protocol
Description: ANI score 50-70 indicates optimal narcotic effect. ANI score > 70 indicated overdosage of narcotic and narcotic should be withheld.~ANI score \< 50 indicates inadequate narcotic and narcotic should be given.
Study NCT01762878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557
Description: Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg
Study NCT02868424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fRPE cells
Description: fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
Study NCT04379154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volatile Organic Compounds analysis
Description: Volatile Organic Compounds analysis in exhaled air by electronic noses
Study NCT03775317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy
Description: The direct, or conventional, laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Macintosh or Miller laryngoscope for direct visualization of the larynx.
Study NCT03297216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17P
Description: Synthetic progestin
Study NCT03297216 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active placebo comparator
Study NCT03213483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronally advanced flap and subepithelial connective tissue graft
Description: The connective tissue graft is obtained by a single line incision from the palate.
Study NCT03213483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally advanced flap and deepithelialized free gingival graft
Description: The connective tissue graft is obtained by deepithelialization of a free gingival graft.
Study NCT03775317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy
Description: The video-assisted laryngoscopy group will undergo the planned nasotracheal intubation utilizing a Storz C-MAC S Video Laryngoscope to allow for indirect visualization of the larynx.
Study NCT04126031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3
Description: Single intravenous infusion of ceftazidime-avibactam over 2 hours
Study NCT04126031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
Description: Multiple intravenous infusions of ceftazidime-avibactam over 2 hours, repeated every 8 hours up to 14 days
Study NCT04045574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The 1T1T concept versus conventional implant loading protocol
Description: Implant placement followed by either a conventional or a delayed loading of a PICN screw-retained crown.
Study NCT02853981 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Harmonic scalpel
Description: a method for liver parenchymal transection
Study NCT02853981 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kelly clamp crush technique
Description: a method for liver parenchymal transection
Study NCT01406652 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage bursectomy
Description: Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions
Study NCT01406652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-stage bursectomy
Description: Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions
Study NCT02620709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hula intervention
Description: Hula and heart health education
Study NCT00976248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Taken orally once a day
Study NCT01763814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block
Description: A visible or palpable cephalad movement of the patella will confirm needle placement.
Study NCT01763814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block non stimulating catheter
Description: A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered off.
Study NCT01763814 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral nerve block stimulating catheter
Description: A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered on.
Study NCT02917330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching and progressive strength training
Description: Intervention implemented by local physiotherapist.16 weeks, three treatment sessions each week. Minimum pause between two treatment sessions is one day. Week 1 and 2: To assure the correct dosage in each exercise and a satisfactory education of the session done at home, all three sessions will be implemented with the physiotherapist the first two weeks. From week 3: Two treatment/training sessions with the physiotherapist and one shorter training session at home.
Study NCT00115557 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice intervention
Description: Performance feedback, academic detailing, practice facilitation, IT support
Study NCT00115557 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Practice intervention 2
Description: Performance feedback only.
Study NCT02177136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid (OCA)
Study NCT02177136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04298645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycaemic response to high GI carbohydrates consumed at morning versus evening meals.
Description: Controlled nutrition trial on the glycaemic response to morning and evening meals with high glycemic index carbohydrates among students with early and late chronotypes.
Study NCT04132336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium/Caffeine (BAY2880376)
Description: Tablet, oral, single dose
Study NCT04132336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen sodium (Aleve)
Description: Tablet, oral, single dose
Study NCT04132336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Tablet, oral, single dose
Study NCT04132336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral, single dose
Study NCT03792724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urelumab + Nivolumab
Description: Treatment with intratumoral urelumab after which Nivolumab will be given.
Study NCT01598350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supramalleolar Orthoses (Cascade)
Description: Walk wearing supramalleolar orthoses - three trial
Study NCT01884311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subgam
Description: Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg/week) for 26 weeks (26 infusions) beginning one week after the last IGIV infusion. Dose of Subgam-VF will then be adjusted based on the ratio of the Immunoglobulin G (IgG) average concentration achieved with Subgam-VF compared to IGIV.
Study NCT03446963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Groups for Health
Description: Group sessions, 5 modules x 1.5 hours (once per week). Modules focus on psychoeducation, mapping existing social networks, examining barriers to engagement in existing networks, goal setting and identifying new groups to join.
Study NCT03646760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HYCR
Description: This group involves a hybrid design, with the frequency of center based cardiac rehabilitation (CBCR) visits and HYCR visits individualized and modified based on the subject's personal preferences and their family, transportation and work constraints. Patients in HYCR will engage in at least one CBCR visit. Patients will have the video app loaded to their smart phone or tablet (or that of a willing to assist family member or friend). HYCR patients receive a chest strap/wrist heart rate device to document HR before, during, and/or after exercise during the TM session. Program education for patients in HYCR will be delivered using the twenty-eight, 7-15 min audio PDF's that are free to access from the Health System's web site.
Study NCT03646760 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBCR
Description: This group will attend 2-3 sessions of cardiac rehabilitation per week at the investigator's Detroit location. Program education for patients in CBCR will be delivered during eight. 1 hour education lectures taught by staff (exercise physiologists and registered dieticians).
Study NCT03142919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative
Study NCT03142919 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lipopolysaccharide
Description: Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative
Study NCT04856124 — intervention group
Intervention type: DRUG
Intervention: Intranasal esketamine
Description: Subjects with a clinically meaningful response to IV racemic ketamine were switched to IN esketamine
Study NCT00969631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin HCl (Cidophage®; CID,Cairo, Egypt), CC (Clomid®; Global Napi Pharmaceuticals,Cairo, Egypt),Cairo, Egypt)
Description: metformin HCl 1500 daily for 6-8 weeks then 100 mg CC for 5 days starting from day 3 of menstruation up to 6 cycles.
Study NCT00969631 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic ovarian diathermy (LOD)
Description: Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
Study NCT01204450 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temsirolimus
Description: 60-230mg/m2 weekly during each 28 day course, for up to 12 courses
Study NCT01204450 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Valproic Acid
Description: All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses
Study NCT05223296 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compare between two procedure for II-IV degree pile excision
Description: LigaSure or diathermy excision of III-IV degree pile?
Study NCT02312063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Study NCT02312063 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Study NCT00523965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amphotericin B deoxycholate
Description: Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions
Study NCT00523965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B with Miltefosine
Description: Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or > 25 kg Miltefosine 50 mg once daily if patient weighs \<25 mg
Study NCT00523965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B and Paromomycin Sulfate
Description: AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
Study NCT00523965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miltefosine + Paromomycin sulfate
Description: oral miltefosine 50mg once daily (\< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
Study NCT00521417 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: short-term dynamic therapy
Study NCT00521417 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: long-term dynamic therapy
Study NCT01878487 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thrombus aspiration (Intravascular Ultrasound catheter (Boston))
Description: There is a single arm in the study where all patients are undergoing primary percutaneous coronary intervention for an acute myocardial infarction.~All patients will have an Intravascular Ultrasound three times:~1. At baseline~2. After thrombus aspiration with a thrombus extraction catheter~3. After stent deployment~We are however assessing the physiological response of patients having an acute myocardial infarction and this is not a test of the devices as such.
Study NCT03606876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT1806 injection
Description: Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).
Study NCT03606876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT1806 injection
Description: Each subject will receive single intravenous drip of 4 mg/kg BAT1806 Injection or Actemra® (EU-licensed and US-licensed).
Study NCT02982798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Rosuvastatin
Description: administration of Metformin + Rosuvastatin
Study NCT02982798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JLP-1310
Description: administration of JLP-1310
Study NCT04206514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person Centered Care - Post Abortion Support
Description: Post abortion phone based support
Study NCT02546336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-Guided Cooled Radiofrequency Hip Denervation
Description: Light neuroleptic anesthesia and skin preparation will be performed. Under Ultrasound guidance, an active probe will be inserted. Sensory and motor stimulation will be administered. Anteroposterior fluoroscopy image will be recorded. Lesioning of articular branches of femoral and obturator nerves via radiofrequency will be performed after lidocaine injection. WOMAC, EQ-5D and SF-12 questionnaires will be used for measuring outcomes postoperatively.
Study NCT03251963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed Dose Enoxaparin
Description: Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
Study NCT03251963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Variable Dose Enoxaparin
Description: Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
Study NCT01157780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza (fish oil)
Description: Patients will receive fish supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period.
Study NCT03142919 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline solution
Study NCT03489044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: To up-titrate Levetiracetam to 500mg (two tablets) twice daily followed by maintenance on Levetiracetam 500mg twice daily for four weeks and then down-titrate to nil over four weeks
Study NCT03489044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: To up-titrate placebo to two tablets twice daily followed by maintenance on placebo two tablets twice daily for four weeks and then down-titrate to nil over four weeks
Study NCT04136691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation training
Description: Burn patient scenario was performed with the intervention group.
Study NCT00939107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal manipulation
Description: Spinal manipulation to the lumbopelvic spine in combination with information about examination findings and advice about back care
Study NCT02304991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liquid Peanut Extract
Description: 5000mcg/ml peanut protein
Study NCT02304991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Glycerin SLIT
Description: pure glycerinated saline solution with caramel coloring to match color
Study NCT00939107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: McKenzie exercises
Description: McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
Study NCT00769795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-A12
Description: IMC-A12 will be administered every 2 weeks for a total of 6 doses at 10 mg/kg per dose. The last dose of IMC-A12 will be at least 2 weeks prior to prostatectomy.
Study NCT00769795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Bicalutamide 50 mg daily orally for 12 weeks
Study NCT00769795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: 10.8 mg subcutaneous once
Study NCT01746446 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care team
Description: Provides additional support to patients, family, and friends.
Study NCT02132897 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose
Description: Carbamazepine CR Tablets 400 milligrams is given orally with 250 mL of water at room temperature.
Study NCT02132897 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tegretol CR 400 Single Dose-Auration CR 400 Single Dose
Description: Auration CR 400 milligrams Single Dose is given orally with 250 mL of water at room temperature.
Study NCT00290589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramuscular methylprednisolone acetate
Description: Intramuscular methylprednisolone acetate 160mg
Study NCT00290589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline intramuscular injection
Study NCT03234400 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring, 25 mg
Description: Vaginal Ring containing 25 mg dapivirine
Study NCT03234400 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring, 100 mg
Description: Vaginal Ring containing 100 mg dapivirine
Study NCT03234400 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring, 200 mg
Description: Vaginal Ring containing 200 mg dapivirine
Study NCT04950842 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JB-101
Description: induced T cell with suppressive function
Study NCT01599702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Isomaltoside 1000
Description: 1500-3000mg IV depending on HB level, sex and body weight
Study NCT02166229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Study NCT01691053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: 50mg once daily